<DOC>
	<DOCNO>NCT00134667</DOCNO>
	<brief_summary>The purpose trial compare whether Macugen ( pegaptanib sodium ) combination PDT Visudyne ( verteporfin ) safe effective slowing leakage fluid within eye thereby stabilize improve vision compare Macugen alone . Patients must recently diagnose predominantly classic wet AMD must eligible PDT .</brief_summary>
	<brief_title>Macugen ( Pegaptanib Sodium ) Alone , Versus Macugen Combination With PDT ( Photodynamic Therapy ) With Visudyne ( Verteporfin ) Patients With Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Subjects either gender ; age 50 year great . Subfoveal choroidal neovascularization ( CNV ) due AMD predominantly classic lesion composition Best correct visual acuity study eye 20/40 20/200 Any prior PDT Visudyne study eye Any previous AMD thermal laser therapy study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>AMD</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Macugen</keyword>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>PDT</keyword>
	<keyword>Visudyne</keyword>
	<keyword>pegaptanib sodium</keyword>
	<keyword>verteporfin</keyword>
	<keyword>Predominantly Classic</keyword>
	<keyword>Age-Related Macular Degeneration ( AMD )</keyword>
</DOC>